Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
24.93
+0.71 (2.93%)
Apr 2, 2026, 10:43 AM EDT - Market open
Beam Therapeutics Revenue
In the year 2025, Beam Therapeutics had annual revenue of $139.74M with 120.01% growth. Beam Therapeutics had revenue of $114.11M in the quarter ending December 31, 2025, with 279.52% growth.
Revenue (ttm)
$139.74M
Revenue Growth
+120.01%
P/S Ratio
17.06
Revenue / Employee
$273,470
Employees
511
Market Cap
2.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 139.74M | 76.23M | 120.01% |
| Dec 31, 2024 | 63.52M | -314.19M | -83.18% |
| Dec 31, 2023 | 377.71M | 316.79M | 520.01% |
| Dec 31, 2022 | 60.92M | 9.08M | 17.51% |
| Dec 31, 2021 | 51.84M | 51.82M | 215,916.67% |
| Dec 31, 2020 | 24.00K | 6.00K | 33.33% |
| Dec 31, 2019 | 18.00K | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.20B |
| Apellis Pharmaceuticals | 1.00B |
| ADMA Biologics | 510.17M |
| Day One Biopharmaceuticals | 158.18M |
| Ascentage Pharma Group International | 82.08M |
| Immunome | 6.94M |
BEAM News
- 17 hours ago - Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine - GlobeNewsWire
- 7 days ago - Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript - Seeking Alpha
- 8 days ago - Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels - Benzinga
- 8 days ago - Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development - GlobeNewsWire
- 4 weeks ago - Beam Therapeutics: Great Potential, But Patience Is Needed - Seeking Alpha
- 5 weeks ago - Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - What's Going On With Beam Therapeutics Stock? - Benzinga
- 5 weeks ago - Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) - GlobeNewsWire